Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

No Association between BRCA1 Immunohistochemical Expression and Tumor Grade, Stage or Overall Survival in Platinum-Treated Epithelial Ovarian Cancer Patients

  • Shawky, Abd El-Aty (Department of Pathology, Faculty of Medicine, Mansoura University) ;
  • El-Hafez, Amal Abd (Department of Pathology, Faculty of Medicine, Mansoura University) ;
  • El-Tantawy, Dina (Department of Pathology, Faculty of Medicine, Mansoura University) ;
  • Hamdy, Rasha (Department of Radiotherapy and Nuclear Medicine, Faculty of Medicine, Mansoura University)
  • Published : 2014.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The aim of this work is to assess the frequency of BRCA1 protein immunohistochemical (IHC) expression in epithelial ovarian cancer (EOC) and to evaluate the association of BRCA1 expression with clinical and pathological characteristics and the overall survival (OS) of patients treated with postoperative platinum-based chemotherapeutic agents. Materials and Methods: This retrospective study was conducted on 35 cases of epithelial ovarian cancer selected from the files of the Pathology Department, Faculty of Medicine, Mansoura University, Egypt. Immunohistochemistry (IHC) was performed for BRCA1 gene protein. BRCA1 expression was compared to patient's age, tumor histology, grade, stage and OS time. Statistical analysis was carried out with the SPSS version 16.0 to assess significant associations. Results: BRCA1 nuclear expression was detected in 40% of EOC, in which a mild increase in the percentage of positive cases was observed with serous histology, stage IV, and grade 3 carcinomas. There was a significant statistical difference in BRCA1 expression with regard to histological subtypes of EOC (p=0.048), but not grade or stage. Mean OS and survival rate were slightly better for BRCA1 expressing group, but there was no statistically significant difference (p=0.528). Conclusions: No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival was noted in platinum-treated epithelial ovarian cancer patients.

Keywords

References

  1. Aida H, Takakuwa K, Nagata H, et al (1998). Clinical features of ovarian cancer in Japanese women with germline mutations of BRCA1. Clin Cancer Res, 4, 235-40.
  2. Altekruse S, Kosary C, Krapcho M, et al (eds). (2010). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/
  3. Ben-David Y, Chetrit A, Hirsh-Yechezkel G, et al (2002). Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol, 20, 463-6. https://doi.org/10.1200/JCO.20.2.463
  4. Bolton KL, Chenevix-Trench G, Goh C, et al (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307, 382-90. https://doi.org/10.1001/jama.2012.20
  5. Boyd J, Sonoda Y, Federici MG, et al (2000). Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA, 283, 2260-5. https://doi.org/10.1001/jama.283.17.2260
  6. Carser JE, Quinn JE, Michie CO, et al (2011). BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol, 123, 492-8. https://doi.org/10.1016/j.ygyno.2011.08.017
  7. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al (2008). Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer. J Clin Oncol, 26, 20-5. https://doi.org/10.1200/JCO.2007.11.6905
  8. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA (1998). RCA1 required for transcription-coupled repair of oxidative NA damage. Science, 281, 1009-12. https://doi.org/10.1126/science.281.5379.1009
  9. Han Y, Wang XB, Xiao N, Liu ZD (2013). mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2987-90. https://doi.org/10.7314/APJCP.2013.14.5.2987
  10. Hasan TN, Shafi G, Syed NA, et al (2013). Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pac J Cancer Prev, 14, 5671-4. https://doi.org/10.7314/APJCP.2013.14.10.5671
  11. Ji T, Zheng ZG, Wang FM, et al (2014). Differential microRNA expression by solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1739-43. https://doi.org/10.7314/APJCP.2014.15.4.1739
  12. Johannsson OT, Ranstam J, Borg A, Olsson H (1998). Survival of BRCA1 breast and ovarian cancer patients: a populationbased study from southern Sweden. J Clin Oncol, 16, 397-404.
  13. Joo JG, Ladi S, Nagy BZ, Langmar Z (2011). Management of hereditary ovarian cancer. Orv Hetil, 152, 1596-608. (Pubmed abstract) https://doi.org/10.1556/OH.2011.29218
  14. Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A (2013). Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran. Asian Pac J Cancer Prev, 14, 4339-45. https://doi.org/10.7314/APJCP.2013.14.7.4339
  15. Lan VTT, Thuan TB, Thu DM, et al (2013). Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer. Asian Pac J Cancer Prev, 14, 7713-8. https://doi.org/10.7314/APJCP.2013.14.12.7713
  16. Lesnock JL, Darcy KM, Tian C, et al (2013). BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer, 108, 1231-7. https://doi.org/10.1038/bjc.2013.70
  17. Li FY, Ren XB, Xie XY, Zhang J (2013). Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev, 14, 7203-6. https://doi.org/10.7314/APJCP.2013.14.12.7203
  18. Lorusso D, Cirillo F, Mancini M, et al (2013). The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. Oncology, 85, 122-7. https://doi.org/10.1159/000353786
  19. Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9. https://doi.org/10.7314/APJCP.2013.14.6.3403
  20. O'Donovan PJ, Livingston DM (2010). BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis, 31, 961-7. https://doi.org/10.1093/carcin/bgq069
  21. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA (1999). Survival in familial, BRCA1-associated, and BRCA2- associated epithelial ovarian cancer. Cancer Res, 59, 868-71.
  22. Prat J, Rib A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol, 36, 861-70. https://doi.org/10.1016/j.humpath.2005.06.006
  23. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP (2009). BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol, 113, 134-42. https://doi.org/10.1016/j.ygyno.2008.12.015
  24. Radosa MP, Hafner N, Camara O, et al (2011). Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Int J Gynecol Cancer, 21, 1399-406. https://doi.org/10.1097/IGC.0b013e318227c990
  25. Rubin SC, Benjamin I, Behbakht K, et al (1996). Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. N Engl J Med, 335, 1413-6. https://doi.org/10.1056/NEJM199611073351901
  26. Sirisabya N, Manchana T, Termrungreunglert W, et al (2007). Prevalence of BRCA1 Expression in Epithelial Ovarian Cancer: Immunohistochemical Study. J Med Assoc Thai, 90, 9-14.
  27. Skytte AB, Waldenstorm M, Rasmussen AA, et al (2011). Identification of BRCA1-deficient ovarian cancers. Acta Obstet Gynecol Scand, 90, 593-9. (Pubmed abstract). https://doi.org/10.1111/j.1600-0412.2011.01121.x
  28. Sowter H M, Ashworth A (2005). BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis, 26, 1651-6. https://doi.org/10.1093/carcin/bgi136
  29. Swisher E (2003). Ovarian cancer associated with inherited mutations in BRCA1. Curr Women Health Rep, 3, 27-32.
  30. Tutt A, Ashworth A (2002). The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med, 8, 571-6. https://doi.org/10.1016/S1471-4914(02)02434-6
  31. Venkitaraman AR (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171-82. https://doi.org/10.1016/S0092-8674(02)00615-3
  32. Werness BA, Ramus SJ, DiCioccio RA, et al (2004). Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner familial ovarian cancer registry. Int J Gynecol Pathol, 23, 29-34. https://doi.org/10.1097/01.pgp.0000101083.35393.cd
  33. Wysham WZ, Mhawech-Fauceglia P, Li H, et al (2012). BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One, 7, 30042. https://doi.org/10.1371/journal.pone.0030042
  34. Yang D, Khan S, Sun Y, et al (2011). Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 306, 1557-65. https://doi.org/10.1001/jama.2011.1456